Navigation Links
Microbubble-delivered combination therapy eradicates prostate cancer in vivo
Date:5/10/2011

Richmond, Va. (May 10, 2011) Cancer researchers are a step closer to finding a cure for advanced prostate cancer after effectively combining an anti-cancer drug with a viral gene therapy in vivo using novel ultrasound-targeted microbubble-destruction (UTMD) technology. The research was conducted by scientists at Virginia Commonwealth University Massey Cancer Center, VCU Institute of Molecular Medicine and School of Medicine, in collaboration with colleagues from Washington University School of Medicine and Sanford-Burnham Medical Research Institute.

In their study, published in the journal Proceedings of the National Academy of Sciences, prostate cancer growth in mice with functioning immune systems was inhibited by sensitizing the cancer cells with the drug Sabutoclax (BI-97C1) and using UTMD technology to deliver a viral gene therapy that expresses the gene mda-7/IL-24. This powerful new approach to treating prostate cancer builds upon prior studies by principle investigator Paul B. Fisher, M.Ph., Ph.D., Thelma Newmeyer Corman Endowed Chair at VCU Massey, professor and chair of the Department of Human and Molecular Genetics in the VCU School of Medicine and director of the VCU Institute of Molecular Medicine.

Sabutoclax works by inhibiting the protein Mcl-1, which is known to promote cell survival by preventing a form of cell suicide known as apoptosis. Fisher's laboratory studies previously showed that the gene mda-7/IL-24 increases apoptosis in tumor cells, prevents tumor growth and blood vessel formation, synergizes with other cancer treatments and also regulates cellular immune responses while having no ill effects on normal, healthy cells. By showing the combined effectiveness of these agents, the researchers have discovered a novel treatment approach for prostate cancer.

"Successful execution of viral gene therapy is typically limited by the body's natural defenses, such as trapping the virus in the liver and attacking the virus with its natural immune system response," says Fisher. "This study not only identifies a potential new therapy for prostate cancer, it also provides a new way of using therapeutic viruses that could transform the way we deliver viral gene therapy."

UTMD uses microscopic, gas-filled bubbles that provide great contrast against soft tissue when viewed using ultrasound equipment. The microbubbles can also be paired with complexes made to bind to specific areas of the body, allowing them to be targeted. In this study, a weakened adenovirus (a virus that is typically associated with respiratory infections) engineered to deliver the tumor-suppressing gene mda-7/IL-24 was joined to the microbubbles and delivered through the blood stream directly into the prostate. UTMD's ability to systematically target a disease site could revolutionize gene therapy.

"Although our studies focused on prostate cancer, in principle, they could be applied to many other cancers," says Fisher. "Additionally, ultrasound-targeted microbubble destruction could deliver directly to cancers other viruses, therapeutic genes not contained in a virus and potentially other therapeutic proteins."

UTMD technology is currently utilized in Phase III clinical trials to treat heart disease. Because the technology is already being applied in the clinic, the researchers plan to partner with clinicians to develop a Phase I clinical trial to evaluate the safety of viral gene therapy using UTMD in patients with prostate cancer.


'/>"/>

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University
Source:Eurekalert

Related biology news :

1. Combination therapy provides hope for cure of dangerous infections of cystic fibrosis patients
2. Killing drug-resistant melanoma requires combination therapy
3. Combination therapy reduced HER2-positive breast cancers
4. Pertuzumab and trastuzumab combination improved efficacy for women with HER2-positive breast cancer
5. Novocure reports data showing TTF therapy in combination with chemotherapy has the potential to increase overall survival for patients with advanced non-small cell lung cancer
6. Grape news: New treatment combination safe alternative to sulfur dioxide
7. Study: Grass, fungus combination affects ecology
8. Investigators identify cleat/natural grass combination may be less likely to result in ACL injury
9. Diabetes drug kills cancer stem cells in combination treatment in mice
10. Old stain in a new combination
11. Latest advances in gene therapy for ocular disease are highlighted in Human Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology ... LCD display is the latest premium product recently added to the range of products ... ... ... 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... will join the faculty of the University of North Carolina Kenan-Flagler Business ... strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial ... Cary 5000 and the 6000i models are higher end machines that use the more ... the spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: